| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0376-8716(00)00123-X |
| P698 | PubMed publication ID | 11064184 |
| P2093 | author name string | N A Ator | |
| P2860 | cites work | Zaleplon and triazolam in humans: acute behavioral effects and abuse potential | Q33870793 |
| Discriminative stimulus effects of alpidem, a new imidazopyridine anxiolytic | Q34319098 | ||
| Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia | Q34473287 | ||
| Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons | Q34533236 | ||
| Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential | Q37977354 | ||
| Pharmacokinetics of the newer benzodiazepines | Q38353433 | ||
| Behavioural pharmacology of food, water and salt intake in relation to drug actions at benzodiazepine receptors | Q38385211 | ||
| A note on the measurement of conditional discrimination | Q41363728 | ||
| Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem | Q42552680 | ||
| Resolution of two biochemically and pharmacologically distinct benzodiazepine receptors | Q45157485 | ||
| Pharmacokinetics and Pharmacodynamics of Triazolam After Two Intermittent Doses in Obese and Normal-Weight Men | Q47353103 | ||
| Discriminative stimulus effects of omega (BZ) receptor ligands: correlation with in vivo inhibition of [3H]-flumazenil binding in different regions of the rat central nervous system | Q48389661 | ||
| The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic | Q48421518 | ||
| Differentiating benzodiazepine- and barbiturate-like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil and zaleplon in two- versus three-lever procedures. | Q51400688 | ||
| Drug discrimination analysis of endogenous neuroactive steroids in rats. | Q51655567 | ||
| Differential generalization to pentobarbital in rats trained to discriminate lorazepam, chlordiazepoxide, diazepam, or triazolam. | Q51761099 | ||
| A tethering system for intravenous and intragastric drug administration in the baboon. | Q51858744 | ||
| A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. | Q52058449 | ||
| Discriminative stimulus properties of CL218872 and chlordiazepoxide in the rat. | Q52244137 | ||
| Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons | Q61037537 | ||
| Novel benzodiazepine receptor ligands: palatable food intake following zolpidem, CGS 17867A, or Ro23-0364, in the rat | Q69375887 | ||
| Pharmacokinetics and anticonvulsant effect of a new hypnotic, CL 284,846, in rats | Q70980548 | ||
| Triazolam Pharmacokinetics After Intravenous, Oral, and Sublingual Administration | Q71826379 | ||
| Evaluation of the discriminative stimulus effects of the novel sedative-hypnotic CL 284,846 | Q72579778 | ||
| Zaleplon pharmacokinetics and absolute bioavailability | Q77352492 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | zaleplon | Q145052 |
| P304 | page(s) | 55-68 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Drug and Alcohol Dependence | Q5308875 |
| P1476 | title | Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons | |
| P478 | volume | 61 |
| Q24644809 | Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond |
| Q37577869 | Comparative tolerability of newer agents for insomnia |
| Q35993507 | Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. |
| Q36799037 | D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog. |
| Q28264334 | GABA site agonist gaboxadol induces addiction-predicting persistent changes in ventral tegmental area dopamine neurons but is not rewarding in mice or baboons |
| Q34630587 | Intravenous self-administration of γ-hydroxybutyrate (GHB) in baboons |
| Q21296639 | Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABA(A) Receptor Modulators? |
| Q34768548 | Novel discriminative stimulus effects of TPA023B, subtype-selective gamma-aminobutyric-acid(A)/benzodiazepine modulator: comparisons with zolpidem, lorazepam, and TPA023 |
| Q46534256 | Oral administration of D-alanine in monkeys robustly increases plasma and cerebrospinal fluid levels but experimental D-amino acid oxidase inhibitors had minimal effect |
| Q35132182 | Principles of drug abuse liability assessment in laboratory animals |
| Q33574884 | Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes |
| Q42604024 | Selectivity in generalization to GABAergic drugs in midazolam-trained baboons |
| Q36539839 | Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons |
| Q61037537 | Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons |
Search more.